<SUBMISSION>
<ACCESSION-NUMBER>0000950148-02-002845
<TYPE>8-K
<PUBLIC-DOCUMENT-COUNT>2
<PERIOD>20021202
<ITEMS>5
<ITEMS>7
<FILING-DATE>20021203
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>ADVANCED BIOTHERAPY INC
<CIK>0000791833
<ASSIGNED-SIC>8731
<STATE-OF-INCORPORATION>NV
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>8-K
<ACT>34
<FILE-NUMBER>000-26323
<FILM-NUMBER>02847015
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>6355 TOPANGA CANYON BLVD
<STREET2>SUITE 510
<CITY>WOODLAND HILLS
<STATE>CA
<ZIP>91367
<PHONE>8188833956
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>6355 TOPANGA CANYON BLVD
<STREET2>SUITE 510
<CITY>WOODLAND HILLS
<STATE>CA
<ZIP>91367
</MAIL-ADDRESS>
<FORMER-COMPANY>
<FORMER-CONFORMED-NAME>ADVANCED BIOTHERAPY CONCEPTS INC
<DATE-CHANGED>19990524
</FORMER-COMPANY>
</FILER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>v86310e8vk.htm
<DESCRIPTION>FORM 8-K  DATED DECEMBER 2, 2002
<TEXT>
<HTML>
<HEAD>
<TITLE>ADVANCED BIOTHERAPY, INC.</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<P align="center"><FONT size="2"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
Washington, DC 20549</B></FONT>

<P align="center"><FONT size="2"><B>FORM 8-K</B></FONT>

<P align="center"><FONT size="2"><B>CURRENT REPORT<BR>
Pursuant to Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934</B></FONT>

<P align="left"><FONT size="2">Date of Report (Date of earliest reported) December&nbsp;2, 2002</FONT>

<P align="center"><FONT size="2">Advanced Biotherapy, Inc.<BR>
(Exact name of registrant as specified in its chapter)</FONT>

<TABLE cellspacing="0" border="0" cellpadding="0" width="100%">
<TR>
        <TD width="32%">&nbsp;</TD>
        <TD width="2%">&nbsp;</TD>
        <TD width="32%">&nbsp;</TD>
        <TD width="2%">&nbsp;</TD>
        <TD width="32%">&nbsp;</TD>
</TR>
<TR valign="bottom">
        <TD align="center"><FONT size="2">Delaware</FONT></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD align="center"><FONT size="2">0-26323</FONT></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD align="center"><FONT size="2">95-0402415</FONT></TD>
</TR>
<TR>
        <TD><HR size="1" noshade></TD>
        <TD><FONT size="1">&nbsp;</FONT></TD>
        <TD><HR size="1" noshade></TD>
        <TD><FONT size="1">&nbsp;</FONT></TD>
        <TD><HR size="1" noshade></TD>
</TR>
<TR valign="top">
        <TD align="center"><FONT size="2">(State or other jurisdiction<BR>
of incorporation)</FONT></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD align="center"><FONT size="2">(Commission<BR>
File Number)</FONT></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD align="center"><FONT size="2">(IRS Employer<BR>
Identification No.)</FONT></TD>
</TR>
</TABLE>
<TABLE cellspacing="0" border="0" cellpadding="0" width="100%">
<TR>
        <TD width="64%">&nbsp;</TD>
        <TD width="2%">&nbsp;</TD>
        <TD width="32%">&nbsp;</TD>
</TR>
<TR valign="bottom">
        <TD align="left"><FONT size="2">6355 Topanga Canyon Boulevard, Suite&nbsp;510<BR>
Woodland Hills, California</FONT></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD align="center"><FONT size="2">91367
</FONT></TD>
</TR>
<TR>
        <TD><HR size="1" noshade></TD>
        <TD><FONT size="1">&nbsp;</FONT></TD>
        <TD><HR size="1" noshade></TD>
</TR>
<TR valign="top">
        <TD align="left"><FONT size="2">(Address of principal
executive offices)</FONT></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD align="center"><FONT size="2">(Zip Code)</FONT></TD>
</TR>
</TABLE>
<P align="left"><FONT size="2">Registrant&#146;s telephone number, including area code (818)&nbsp;883-6716</FONT>


<P align="center"><FONT size="2">&nbsp;
</FONT>

<!-- PAGEBREAK -->
<P><HR noshade><P>


<!-- TOC -->
<A name="toc"><DIV align="CENTER" style="page-break-before:always"><U><B>TABLE OF CONTENTS</B></U></DIV></A>

<P><CENTER>
<TABLE border="0" width="90%" cellpadding="0" cellspacing="0">
<TR>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="76%"></TD>
</TR>
<TR><TD></TD><TD colspan="8"><A HREF="#000">Item&nbsp;5. OTHER EVENTS.</A></TD></TR>
<TR><TD></TD><TD colspan="8"><A HREF="#001">Item&nbsp;7. FINANCIAL STATEMENTS AND EXHIBITS</A></TD></TR>
<TR><TD colspan="9"><A HREF="#002">Signatures</A></TD></TR>
<TR><TD colspan="9"><A HREF="#003">INDEX TO EXHIBITS</A></TD></TR>
<TR><TD colspan="9"><A HREF="v86310exv99w1.htm">EXHIBIT 99.1</A></TD></TR>
</TABLE>
</CENTER>
<!-- /TOC -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>






<!-- link2 "Item&nbsp;5. OTHER EVENTS." -->
<DIV align="left"><A NAME="000"></A></DIV>
<P align="left"><FONT size="2">Item&nbsp;5. OTHER EVENTS.</FONT>

<P><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The registrant published a press release on December&nbsp;2, 2002, which
reported that Advanced Biotherapy, Inc. has closed the private placement of its
2002 Subordinated Convertible Pay-In-Kind Notes, and has reported its financial
results for the nine months ended September&nbsp;30, 2002.
</FONT>
<!-- link2 "Item&nbsp;7. FINANCIAL STATEMENTS AND EXHIBITS" -->
<DIV align="left"><A NAME="001"></A></DIV>
<P align="left"><FONT size="2">Item&nbsp;7. FINANCIAL STATEMENTS AND EXHIBITS</FONT>

<P><FONT size="2">(c)&nbsp; Exhibits.
</FONT>
<CENTER>
<TABLE cellspacing="0" border="0" cellpadding="0" width="85%">
<TR valign="bottom">
        <TD width="9%">&nbsp;</TD>
        <TD width="5%">&nbsp;</TD>
        <TD width="86%">&nbsp;</TD>
</TR>
<TR valign="bottom">
        <TD nowrap align="center"><FONT size="1">Designation</FONT></TD>
        <TD><FONT size="1">&nbsp;</FONT></TD>
        <TD nowrap align="center"><FONT size="1">Description of Exhibit</FONT></TD>
</TR>
<TR valign="bottom">
        <TD nowrap align="center"><HR size="1" noshade></TD>
        <TD><FONT size="1">&nbsp;</FONT></TD>
        <TD nowrap align="center"><HR size="1" noshade></TD>
</TR>
<TR valign="bottom">
        <TD valign="top" align="center"><FONT size="2">99.1</FONT></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD align="left" valign="top"><FONT size="2">
Press Release, dated December&nbsp;2, 2002</FONT></TD>
</TR>
</TABLE>
</CENTER>
<!-- link1 "Signatures" -->
<DIV align="left"><A NAME="002"></A></DIV>
<P align="center"><FONT size="2">Signatures</FONT>

<P><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
</FONT>
<TABLE cellspacing="0" border="0" cellpadding="0" width="100%">
<TR>
        <TD width="50%">&nbsp;</TD>
        <TD width="1%">&nbsp;</TD>
        <TD width="49%">&nbsp;</TD>
</TR>
<TR valign="top">
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD colspan="2"><FONT size="2">ADVANCED BIOTHERAPY, INC.<BR> (Registrant)</FONT></TD>
</TR>

<TR><TD>&nbsp;<BR>&nbsp;</TD></TR>
<TR valign="top">
        <TD><FONT size="2">Date: December&nbsp;2, 2002</FONT></TD>
        <TD><FONT size="2">By:&nbsp;</FONT></TD>
        <TD align="left"><FONT size="2">/s/ Edmond Buccellato</FONT></TD>
</TR>
<TR>
        <TD colspan="2"><FONT size="1">&nbsp;</FONT></TD>
        <TD><HR size="1" noshade color="#000000"></TD>
</TR>
<TR valign="top">
        <TD colspan="2">&nbsp;</TD>
        <TD><FONT size="2">Edmond Buccellato, President and CEO</FONT></TD>
</TR>
</TABLE>

<!-- link1 "INDEX TO EXHIBITS" -->
<DIV align="left"><A NAME="003"></A></DIV>
<P align="center"><FONT size="2">INDEX TO EXHIBITS</FONT>

<CENTER>
<TABLE cellspacing="0" border="0" cellpadding="0" width="85%">
<TR valign="bottom">
        <TD width="9%">&nbsp;</TD>
        <TD width="5%">&nbsp;</TD>
        <TD width="86%">&nbsp;</TD>
</TR>
<TR valign="bottom">
        <TD nowrap align="center"><FONT size="1">Exhibit</FONT></TD>
        <TD><FONT size="1">&nbsp;</FONT></TD>
        <TD nowrap align="center"><FONT size="1">Description</FONT></TD>
</TR>
<TR valign="bottom">
        <TD nowrap align="center"><HR size="1" noshade></TD>
        <TD><FONT size="1">&nbsp;</FONT></TD>
        <TD nowrap align="center"><HR size="1" noshade></TD>
</TR>
<TR valign="bottom">
        <TD valign="top" align="center"><FONT size="2">99.1</FONT></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD align="left" valign="top"><FONT size="2">
Text of Press Release, dated December&nbsp;2, 2002</FONT></TD>
</TR>
</TABLE>
</CENTER>
<P align="center"><FONT size="2">&nbsp;
</FONT>

</BODY>
</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>v86310exv99w1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
<TITLE>ADVANCED BIOTHERAPY, INC.</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<P><FONT size="2">EXHIBIT 99.1
</FONT>
<P align="center"><FONT size="2"><B>Advanced Biotherapy, Inc. Closes Convertible Note Placement and Reports its Financial Results for the Nine<BR>
Months Ended September&nbsp;30, 2002</B></FONT>

<P><FONT size="2">WOODLAND HILLS, Calif.&#151; (BW HealthWire)&#151;December&nbsp;2, 2002&#151; Advanced Biotherapy,
Inc. (OTCBB: ADVB &#151; news) announced today that it has closed the private
placement of its 2002 Subordinated Convertible Pay-In-Kind Notes.
</FONT>
<P><FONT size="2">Mr.&nbsp;Edmond Buccellato, President and Chief Executive Officer, stated &#147;that the
placement of $500,000.00 of convertible notes on November&nbsp;19, 2002 with an
individual accredited investor, now places the Company&#146;s cash position at
approximately $3.1&nbsp;million as of November&nbsp;27, 2002. As with our previous
convertible debt and note offerings, the principal amount and related accrued
interest is convertible to common stock at $0.25 per share. This most recently
issued convertible note will bear interest at 12.5% per annum, payable
semi-annually in cash or at the Company&#146;s option, in additional convertible
notes. The note is due, unless converted to common stock prior to maturity, on
June&nbsp;1, 2006.&#148;
</FONT>
<P><FONT size="2">Mr.&nbsp;Buccellato further commented, &#147;As indicated in our quarterly financial
statements filed with the Securities and Exchange Commission on November&nbsp;12,
2002, the Company had approximately $2.7&nbsp;million in cash and short-term
investments as of September&nbsp;30, 2002. For the twelve-month period subsequent to
September&nbsp;30, 2002, the Company anticipates that its minimum cash requirements
to continue as a going concern will be less than $1,500,000, and therefore,
believes that it has adequate cash to maintain operations during that period.
He further stated &#147;that management of the Company is focused and responsibly
executing its business plan on behalf of the stockholders.&#148;
</FONT>
<P><FONT size="2">For the nine months ended September&nbsp;30, 2002, the Company realized a net loss
of $1,072,710 compared to a net loss of $726,165 for the nine months ended
September&nbsp;30, 2001. The Company&#146;s increases in expenses over the nine months
ended September&nbsp;30, 2001 consists primarily of the following: increased
research and development expenses in the amount of $92,777, increased
expenditures in the aggregate amount of $193,195 for professional fees
primarily related to amendments to its registration statement and other
regulatory filing requirements with the Securities and Exchange Commission,
other corporate matters, and payment of $60,000 to Mr.&nbsp;Lawrence Loomis, one of
the Company&#146;s directors, for consulting services related to the placement of
the Company&#146;s convertible notes, increased interest expense in the amount of
$115,085 related to the Company&#146;s convertible subordinated debt and
subordinated convertible pay-in-kind notes, increased depreciation and
amortization in the amount of $12,201, and increased travel expenses in the
amount of $22,526 related to business development and other Company matters,
and increased general and administrative expenses in the amount of $8,628, all
net of decreased directors&#146; fees of $23,280, decreased salaries and benefits of
$27,113, decreased rent of $33,962, decreased telephone and communications of
$8,921 and decreased office expenses in the amount of $9,921.
</FONT>
<P><FONT size="2">Statements made in this news release, other than statements of historical fact,
are forward-looking statements and are subject to a number of uncertainties
that could cause actual results to differ materially from the anticipated
results or other expectations expressed in our forward-looking statements. The
risks and uncertainties which may affect the development, operations and
results of our business include, but are not limited to the following: risks
associated with clinical trials, the uncertainties of research and product
development programs, the uncertainties of the regulatory approval process, the
risks of competitive products, the risks of our current capital resources, the
uncertainties as to the availability of future capital and our future capital
requirements, and the risks associated with the extent and breadth of the
Company&#146;s patent portfolio. The prior discussions of the effect of the patents
issued and pending involve risks and uncertainties, including but not limited
to the risks that third parties may be successful in challenging such patents;
or that granted claims may be held invalid or interpreted differently by a
court of law; or that new technologies will be developed that are superior in
treating the diseases targeted by Advanced Biotherapy, Inc. Readers are
cautioned not to place reliance on these forward-looking statements, which
speak only as of the date the statements were made. See the Company&#146;s public
filings with the Securities and Exchange Commission for further information
about risks and uncertainties that may affect the Company and the results or
expectations expressed in our forward-looking statements, including the section
captioned &#147;Factors That May Affect The
</FONT>
<P align="center"><FONT size="2">&nbsp;
</FONT>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<P><FONT size="2">Company&#148; contained in the Company&#146;s Annual Report on Form&nbsp;10-KSB for the fiscal
year ended December&nbsp;31, 2001.
</FONT>
<P><FONT size="2">CONTACT:
</FONT>
<P><FONT size="2">Advanced Biotherapy, Inc.
</FONT>
<P><FONT size="2">Edmond Buccellato, 818/883-6716
</FONT>
<P><FONT size="2">www.advancedbiotherapy.com
</FONT>
<P><FONT size="2">SOURCE: Advanced Biotherapy, Inc.
</FONT>

<P align="center"><FONT size="2">&nbsp;</FONT>


</BODY>
</HTML>

</TEXT>
</DOCUMENT>
</SUBMISSION>
